GLP-1 enforcement beyond FDA: Justice Department and state attorney general records
As of Nov 15, 2026, this index holds 10 Justice Department or state attorney general actions naming 8 firms over the sale or advertising of GLP-1 drugs: 1 from Justice Department press releases and 9 from state attorney general press releases. Lawsuits, charges, letters and investigative demands are allegations, not findings, and are labeled that way.
Each row is one action read from an official press release. The action type repeats the release’s own wording, and the quote under the table is the release’s sentence naming the firm. A firm’s name links to its page in this index. FDA’s own records on online and telehealth sellers are separate: FDA has posted 125 GLP-1 warning letters to companies it labels telehealth, online sellers or internet pharmacies, and 140 GLP-1 warning letters that name a website (see all FDA warning letters).
| Release | |||||
|---|---|---|---|---|---|
| Jul 23, 2026 | U.S. Attorney’s Office, Western District of Michigan | Sentencing | MilestonePurity.com | Semaglutide, Tirzepatide | justice.gov |
| May 6, 2026 reports a settlement from June 2025 | Connecticut Attorney General | Settlement | Advanced Medical Weight Loss, East Hartford, CT | GLP-1 drugs (no ingredient named for this firm) | portal.ct.gov |
| May 6, 2026 | Connecticut Attorney General | Settlement agreement | Made-in-China | GLP-1 drugs (no ingredient named for this firm) | portal.ct.gov |
| May 6, 2026 | Connecticut Attorney General | Settlement | Radiance Medspa, Avon, CT | Semaglutide, Tirzepatide | portal.ct.gov |
| Jan 12, 2026 | Alabama Attorney General | Settlement | Aurora IV and Wellness, Cullman, AL | Semaglutide, Tirzepatide | alabamaag.gov |
| Dec 3, 2025 | Connecticut Attorney General | Cease and desist letters (allegations, not findings) | CT Weight Loss Shot, Danbury, CT; Vigorous 360 Wellness, Brookfield, CT; Radiance Medspa, Avon, CT | Semaglutide, Tirzepatide | portal.ct.gov |
| Nov 10, 2025 | Alabama Attorney General | Lawsuit and temporary restraining order (allegations, not findings) | Aurora IV and Wellness, Cullman, AL | Semaglutide, Tirzepatide | alabamaag.gov |
| Aug 5, 2025 | Connecticut Attorney General | Settlement | Triggered Brand | Semaglutide, Tirzepatide | portal.ct.gov |
| May 21, 2025 | Connecticut Attorney General | Civil investigative demand (an investigation, not a finding) | Made In China | Semaglutide, Tirzepatide | portal.ct.gov |
| May 21, 2025 | Connecticut Attorney General | Lawsuit (allegations, not findings) | Triggered Brand, Florida | GLP-1 drugs (no ingredient named for this firm) | portal.ct.gov |
What each release says
- U.S. Attorney’s Office, Western District of Michigan, Jul 23, 2026, “Gobles Man Sentenced for Selling Chinese Drugs Without FDA Approval”: “www.MilestonePurity.com. Both websites claimed that the drugs were “for research purposes only” even though Piper and his co-conspirators knew that customers would be using them personally.”
- Connecticut Attorney General, May 6, 2026, “Attorney General Tong Announces Online Platform to Cease Bootleg GLP-1 Weight Loss Drug Sales”: “Attorney General Tong reached a similar settlement with Advanced Medical Weight Loss of East Hartford in June 2025.”
- Connecticut Attorney General, May 6, 2026, “Attorney General Tong Announces Online Platform to Cease Bootleg GLP-1 Weight Loss Drug Sales”: “Made-in-China cooperated with the investigation and has now entered into a settlement agreement with Connecticut that prohibits manufacturers from using the platform to advertise or sell GLP-1s to customers in the United States.”
- Connecticut Attorney General, May 6, 2026, “Attorney General Tong Announces Online Platform to Cease Bootleg GLP-1 Weight Loss Drug Sales”: “Also today, Attorney General Tong announced a settlement with Radiance Medspa of Avon, which advertised and prescribed non-FDA approved compounded semaglutide and/or tirzepatide GLP-1 weight loss injections.”
- Alabama Attorney General, Jan 12, 2026, “Attorney General Marshall Settles Lawsuit with Cullman Clinic for Administering Dangerous, Unapproved Weight Loss Drugs”: “Attorney General Steve Marshall announced the state settled a lawsuit with Aurora IV and Wellness, a Cullman-based IV infusion clinic”
- Connecticut Attorney General, Dec 3, 2025, “Attorney General Tong Announces New Developments in Crackdown on Bootleg GLP-1 Weight Loss Drugs”: “Companies receiving the letters include CT Weight Loss Shot, which operates CT Weight Loss Shot in Danbury and Vigorous 360 Wellness in Brookfield and Radiance Medspa in Avon.” These are allegations; the release does not report a finding or judgment on them.
- Alabama Attorney General, Nov 10, 2025, “Attorney General Steve Marshall Files Suit Against Cullman IV Infusion Clinic for Administering Dangerous, Unapproved Weight Loss Drugs”: “the Cullman County Circuit Court granted his request for a temporary restraining order against Aurora IV and Wellness, a Cullman-based IV infusion clinic” These are allegations; the release does not report a finding or judgment on them.
- Connecticut Attorney General, Aug 5, 2025, “Bootleg GLP-1 Weight Loss Drug Distributor to Cease Unlawful Sales in Settlement with State”: “Attorney General William Tong announced today that Triggered Brand will cease all sales of bootleg GLP-1 weight loss drugs, resolving a lawsuit brought by the state in May alleging violations of the Connecticut Unfair Trade Practices Act.”
- Connecticut Attorney General, May 21, 2025, “Attorney General Tong Sues GLP-1 Weight Loss Drug Distributor Triggered Brand”: “Attorney General Tong has also issued a Civil Investigative Demand to Made In China, a Chinese international trade platform that advertises and sells "research grade" GLP-1s to United States consumers as injectable weight loss medications.” An investigative demand asks for information; the release does not report a finding.
- Connecticut Attorney General, May 21, 2025, “Attorney General Tong Sues GLP-1 Weight Loss Drug Distributor Triggered Brand”: “The lawsuit names Triggered Brand, a Florida-based company, alleging violations of the Connecticut Unfair Trade Practices Act and statutes prohibiting the practice of pharmacy without a license.” These are allegations; the release does not report a finding or judgment on them.
What was searched
This index read every press release on justice.gov’s press release list dated Jan 1, 2026 to Nov 14, 2026 (18,139 releases read through the department’s public press release API) and found 9 releases naming semaglutide, tirzepatide, another GLP-1 drug or a GLP-1 brand name.
State attorney general releases were found by searching for GLP-1, semaglutide and tirzepatide actions and then read on each office’s own website. This is not a complete list of every state’s actions: only the releases in the table were read.
Sources not read
- Federal Trade Commission (ftc.gov cases and press releases): not read because the FTC website answered this index’s requests with an error page instead of the page requested, so FTC cases and press releases were not read; this index does not work around blocks (checked Nov 7, 2026).
- Justice Department press releases dated before January 1, 2026: not read because justice.gov’s release pages answer automated requests with a bot check, so releases are read only through the department’s press release API, which this index reads back to January 1, 2026; earlier releases found by search were not read (checked Nov 7, 2026).
- Ohio Attorney General: not read because the Ohio Attorney General’s website did not respond to this index’s requests (checked Nov 7, 2026).
Questions answered from these records
- Have state attorneys general taken action against GLP-1 weight loss clinics and online sellers?
- Has the Justice Department brought cases over illegal semaglutide or tirzepatide sales?
- Which companies did FDA warn for selling semaglutide online?
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
- U.S. Department of Justice press releases (justice.gov press release API)
- Connecticut Attorney General: Attorney General Tong Announces Online Platform to Cease Bootleg GLP-1 Weight Loss Drug Sales
- Alabama Attorney General: Attorney General Marshall Settles Lawsuit with Cullman Clinic for Administering Dangerous, Unapproved Weight Loss Drugs
- Connecticut Attorney General: Attorney General Tong Announces New Developments in Crackdown on Bootleg GLP-1 Weight Loss Drugs
- Alabama Attorney General: Attorney General Steve Marshall Files Suit Against Cullman IV Infusion Clinic for Administering Dangerous, Unapproved Weight Loss Drugs
- Connecticut Attorney General: Bootleg GLP-1 Weight Loss Drug Distributor to Cease Unlawful Sales in Settlement with State
- Connecticut Attorney General: Attorney General Tong Sues GLP-1 Weight Loss Drug Distributor Triggered Brand
- FDA warning letters (fda.gov full-text search)
Records last pulled Nov 15, 2026. Every entry links to the original public record.